Press Releases

 
Press Releases
  Date Title View
Nov 5, 2015
LEXINGTON, Mass., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it will issue its financial and operating results for the third quarter ended September 30, 2015 on Thursday, November 12, ...
PDF
Sep 29, 2015
LEXINGTON, Mass., Sept. 29, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today announced that it has enrolled the first patient in a Phase IIa clinical trial of NS2 for the treatment of allergic conjunctivitis. ...
PDF
Sep 9, 2015
LEXINGTON, Mass., Sept. 9, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that novel data on the potential of its lead product candidate, NS2, to treat Succinic Semi-aldehyde Dehydrogenase (SSADH)...
PDF
Aug 11, 2015
LEXINGTON, Mass., Aug. 11, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced its financial results for the second quarter and six months ended June 30, 2015. Todd C. Brady, M.D., Ph.D., Presi...
PDF
Aug 5, 2015
LEXINGTON, Mass., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will present at the Canaccord Genuity 35th Annual Growth Con...
PDF
Jul 28, 2015
LEXINGTON, Mass., July 28, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it will issue its financial results for the second quarter ended June 30, 2015 on Tuesday, August 11, 2015, prior to ...
PDF
Jun 29, 2015
LEXINGTON, Mass., June 29, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it will visit the Nasdaq MarketSite in Times Square on Monday, June 29th. In honor of the occasion, Todd C. B...
PDF
May 22, 2015
LEXINGTON, Mass., May 22, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that the underwriters for its recently completed underwritten public offering of common stock have partially exercised thei...
PDF
May 13, 2015
Initiated Two Phase II Clinical Trials and Secured $9.0 Million In Net Proceeds Through Two Private Placements In Q1 Follow-On Public Offering Resulting in $18.8 Million In Net Proceeds Expected to Close in May LEXINGTON, Mass., May 13, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology co...
PDF
May 11, 2015
LEXINGTON, Mass., May 11, 2015 (GLOBE NEWSWIRE) -- Aldeyra Therapeutics, Inc. (Nasdaq:ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to free aldehydes, today announced that it will issue its financial results for the first quarter ended March 31, 2015 on Wednesday, May 13, 2015, prior to th...
PDF
Page: FirstPrevious ...
9
... NextLast